id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-346811-gorp9n1g	Hippisley-Cox, Julia	Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people	2020-07-31		.txt	text/plain	5104	275	50	We report a large, population-based study where we examined the drug histories of approximately 20% of all patients tested positive for coronavirus in England to determine if there was an independent association between ACE inhibitor and ARB drug prescription and severe COVID-19 disease susceptibility and progression. We extracted data from the GP record for explanatory and potential confounding variables including variables with some evidence of being risk factors for COVID-19 disease or severe disease as measured by ICU admission and variables likely to influence prescribing of ACE inhibitors and ARB medications. In this very large population-based study, ACE inhibitor and ARB prescriptions were associated with a reduced risk of COVID-19 RT-PCR positive disease, having adjusted for a wide range of demographic factors, potential comorbidities and other medication. 11 In our study, prior prescription of ACE inhibitor and ARB drugs did not have a significant effect on the risk of patients developing COVID-19 disease severe enough to require ICU care.	./cache/cord-346811-gorp9n1g.txt	./txt/cord-346811-gorp9n1g.txt